CLA
Conjugated linoleic acid is a family of linoleic-acid isomers, not one molecular exposure. Trials report small and inconsistent body-composition effects, and formulation-specific lipid changes limit broad inference.
Pharmacokinetic model
A route-level PK model for cla is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.
Key facts
- Category
- Fatty Acid Supplement
- Suggested cadence
- once daily
Research behind this entry
-
The efficacy of long-term conjugated linoleic acid supplementation on body composition in overweight and obese individuals: a systematic review and meta-analysis of randomized clinical trials
Seven trials lasting at least six months produced small pooled weight and fat-mass differences, while four had serious reporting flaws. The authors judged clinical relevance uncertain and noted gastrointestinal adverse…
-
Conjugated linoleic acid supplementation for 1 y reduces body fat mass in healthy overweight humans
A 180-person, one-year randomized trial found lower fat mass with two CLA formulations, but LDL, HDL, and lipoprotein(a) changed unfavorably in specific active groups. Results belong to the tested isomer mixtures and do…
-
The Effect of Conjugated Linoleic Acid Supplementation on Densitometric Parameters in Overweight and Obese Women-A Randomised Controlled Trial.
This citation reports a human clinical study involving CLA. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
3 published studies referenced in the app, each with a plain-language summary.